Cargando…

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy

BACKGROUND: Although the prognostic biomarkers associated with colorectal cancer (CRC) survival are well known, there are limited data on the association between the molecular characteristics and survival after recurrence (SAR). The purpose of this study was to assess the association between pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Dae-Won, Han, Sae-Won, Cha, Yongjun, Bae, Jeong Mo, Kim, Hwang-Phill, Lyu, Jaemyun, Han, Hyojun, Kim, Hyoki, Jang, Hoon, Bang, Duhee, Won, Jae-Kyung, Jeong, Seung-Yong, Park, Kyu Joo, Kang, Gyeong Hoon, Kim, Tae-You
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501409/ https://www.ncbi.nlm.nih.gov/pubmed/31060539 http://dx.doi.org/10.1186/s12885-019-5650-0

Ejemplares similares

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021)

‘Shotgun DNA synthesis’ for the high-throughput construction of large DNA molecules
por: Kim, Hwangbeom, et al.
Publicado: (2012)

p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: Oh, Hyeon Jeong, et al.
Publicado: (2019)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing
por: Kang, Jun-Kyu, et al.
Publicado: (2020)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2015)

Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
por: Lee, Dae-Won, et al.
Publicado: (2015)

NFATC3–PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines
por: Jang, Jee-Eun, et al.
Publicado: (2019)

Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect rare mutations in circulating tumor DNA
por: Ahn, Jinwoo, et al.
Publicado: (2017)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
por: Min, Byung-Hoon, et al.
Publicado: (2011)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas
por: Lee, Yunbeom, et al.
Publicado: (2021)

FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
por: Cha, Yongjun, et al.
Publicado: (2018)

Reply to ‘Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system”
por: Bae, Jeong Mo, et al.
Publicado: (2018)

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system
por: Bae, Jeong Mo, et al.
Publicado: (2017)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
por: Cha, Yongjun, et al.
Publicado: (2016)

Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer
por: SU, YUQI, et al.
Publicado: (2015)

RNA editing in RHOQ promotes invasion potential in colorectal cancer
por: Han, Sae-Won, et al.
Publicado: (2014)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
por: Ruzzo, Annamaria, et al.
Publicado: (2014)

Highly selective retrieval of accurate DNA utilizing a pool of in situ-replicated DNA from multiple next-generation sequencing platforms
por: Lim, Hyeonseob, et al.
Publicado: (2018)

Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
por: Kim, Jung Ho, et al.
Publicado: (2015)

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
por: Cha, Yongjun, et al.
Publicado: (2023)

A high-throughput optomechanical retrieval method for sequence-verified clonal DNA from the NGS platform
por: Lee, Howon, et al.
Publicado: (2015)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

Polymorphism in miR-146a associated with clinical characteristics and outcomes in gastric cancer patients treated with adjuvant oxaliplatin and fluoropyrimidines
por: Liao, Yu-Qian, et al.
Publicado: (2015)

Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers
por: Cho, Nam-Yun, et al.
Publicado: (2020)

Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing
por: Han, Sae-Won, et al.
Publicado: (2013)

Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II/III Colorectal Cancers Treated with Adjuvant Chemotherapy
por: Oh, Hyeon Jeong, et al.
Publicado: (2019)

EBS-seq: enrichment-based method for accurate analysis of 5-hydroxymethylcytosine at single-base resolution
por: Lee, Jaywon, et al.
Publicado: (2023)

Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
por: Lee, Dae-Won, et al.
Publicado: (2020)

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
por: Kim, Ryul, et al.
Publicado: (2022)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
por: Lee, Jeong Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sdp8cnl3rkvqvda3nireonfb3n